These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30139827)

  • 1. CAR T cells find strength in polyfunction.
    Davila ML
    Blood; 2018 Aug; 132(8):769-770. PubMed ID: 30139827
    [No Abstract]   [Full Text] [Related]  

  • 2. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond CD19 CAR-T cells in lymphoma.
    Leung WK; Ayanambakkam A; Heslop HE; Hill LC
    Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
    Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
    J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quantitative method for measuring the transfection efficiency of CD19-directed chimeric antigen receptor in target cells.
    Fang N; Zhong N; Gu T; Wang Y; Guo X; Ji S
    Adv Clin Exp Med; 2019 Feb; 28(2):159-164. PubMed ID: 30516883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
    Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
    Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
    Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
    Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
    Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
    J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic Procedures for Detection and Cytotoxicity of Chimeric Antigen Receptors.
    Mihara K; Yoshida T; Bhattacharyya J
    Methods Mol Biol; 2019; 1904():299-306. PubMed ID: 30539476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
    Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
    J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.